Načítá se...
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Neprilysin is a widely expressed peptidase with broad substrate specificity that preferentially hydrolyses oligopeptide substrates, many of which regulate the cardiovascular, nervous and immune systems. Emerging evidence suggests that neprilysin also hydrolyses peptides that play an important role i...
Uloženo v:
| Vydáno v: | Diabetologia |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6579747/ https://ncbi.nlm.nih.gov/pubmed/31089754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-019-4889-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|